AGMB
Agomab Therapeutics NV
$17.82
▲ +29.04%$17.82▲ +11.38%
over 1Y
L $9.61EODHDH $17.82
Today+29.0%
1W+8.7%
1M+13.5%
3M+23.7%
YTD-18.9%
1Y-18.9%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Strong Buy
Mixed signals in the latest filings.
Agomab Therapeutics NV shows limited reported revenue.
On these fundamentals, AGMB screens as SELL on the SEC figures.
Financials · annual, by fiscal year
No income data filed.
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$680M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗6-KPeriod ending 2026-06-232026-06-23open ↗6-KPeriod ending 2026-05-272026-05-27open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-06open ↗6-KPeriod ending 2026-04-242026-04-24open ↗20-FPeriod ending 2025-12-312026-04-23open ↗SCHEDULE 13GFiling2026-04-16open ↗3Period ending 2026-03-182026-03-18open ↗3Period ending 2026-03-182026-03-18open ↗3Period ending 2026-03-182026-03-18open ↗3Period ending 2026-03-182026-03-18open ↗
Frequently asked
- Is Agomab Therapeutics NV (AGMB) a buy?
- AGMB currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
Sources: SEC EDGAR (CIK 0002020932, latest 6-K filed 2026-06-23) · EODHD · as of 7/1/2026, 3:33:18 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.